8-K: Catheter Precision Reports 15% Quarter-Over-Quarter Revenue Growth and Announces Reverse Stock Split

Catheter Precision announced a 15% quarter-over-quarter revenue increase, driven by initial sales of its LockeT device, and a 1-for-10 reverse stock split effective July 15, 2024.

Summary

• Catheter Precision reported preliminary unaudited revenue of $94,840 for the second quarter of 2024, which includes $40,500 from initial sales of its LockeT device and $54,340 from VIVO product sales.
• The company's total revenue for the first six months of 2024 reached $176,923.
• A 1-for-10 reverse stock split will be effective on July 15, 2024, reducing the number of outstanding shares from approximately 8,387,631 to 838,763.
• The reverse stock split was approved by the board of directors after being granted discretion by stockholders at a special meeting on July 3, 2024.
• The company's common stock will continue to trade on the NYSE American under the symbol VTAK after the split.

Sentiment

Score: 4

Explanation: While the company shows some positive signs with revenue growth and initial product sales, the low absolute revenue numbers, the need for a reverse stock split, and the numerous risk factors outlined in the document suggest a cautious outlook. The sentiment is therefore slightly negative.

Positives

• The company experienced a 15% quarter-over-quarter revenue growth, indicating positive sales momentum.
• The initial sales of the LockeT device mark a significant milestone for the company.
• The onboarding of a new sales team, including the hiring of a new Chief Commercial Officer, is showing early promise.
• The company has established a growing pipeline of potential customers, suggesting future revenue growth potential.

Negatives

• The company's total revenue for the quarter was only $94,840, which is relatively low.
• The company's total revenue for the first six months of 2024 was $176,923, which is also relatively low.
• The reverse stock split, while not inherently negative, is often a sign of a struggling stock price.

Risks

• The company faces risks related to the acceptance of its products by the medical community.
• There is a risk that customers and distributors may not make additional purchases in the future.
• The company's business relationships could be disrupted by geopolitical events.
• The company's cash needs may continue to exceed its liquidity.
• The company may not be able to achieve profitability without product expansion and growth.
• The company's internal controls and disclosure controls were not effective as of December 31, 2023 and March 31, 2024.
• The company faces competition from companies with greater resources.
• The company's operations are subject to FDA regulatory requirements and potential product liability risks.
• Changes in trade policies could negatively impact the company's average selling prices.

Future Outlook

The company anticipates future revenue growth based on a growing pipeline of potential customers and the initial success of its new sales team. However, the company acknowledges that these are forward-looking statements subject to risks and uncertainties.

Management Comments

• We are pleased to announce these preliminary unaudited revenues, said David Jenkins, CEO and Executive Chairman of Catheter Precision.
• The very initial results of the onboarding of our new sales team, completed with the hire of Marie Claude Jaques as our new Chief Commercial Officer during May, are showing promise.
• The pipeline of potential customers is established and growing, giving us good insight for future revenue growth.

Industry Context

The company operates in the competitive medical device industry, specifically in the field of cardiac electrophysiology. The announcement of initial sales of the LockeT device and the 15% quarter-over-quarter revenue growth suggests the company is making progress in a challenging market. The reverse stock split is a common strategy for companies with low share prices to regain compliance with exchange listing requirements.

Comparison to Industry Standards

• The revenue figures are relatively low compared to established medical device companies, which often report revenues in the millions or billions of dollars per quarter.
• Companies like Medtronic, Abbott, and Boston Scientific, which are major players in the cardiac electrophysiology market, have significantly larger revenue streams and market capitalization.
• The 15% quarter-over-quarter growth is a positive sign, but the absolute revenue numbers are still small, indicating that the company is in an early stage of commercialization.
• The reverse stock split is a common strategy for companies with low share prices to regain compliance with exchange listing requirements, but it does not change the underlying value of the company.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own due to the reverse stock split, but their percentage ownership will remain the same.
• The reverse stock split may impact the stock price, potentially affecting shareholder value.
• The company's employees may be impacted by the company's financial performance and future growth prospects.
• Customers may benefit from the company's innovative products, but the company's financial stability could impact its ability to support them.
• Suppliers may be impacted by the company's ability to purchase components and finished products.

Next Steps

• The company will implement a 1-for-10 reverse stock split effective July 15, 2024.
• The company will continue to focus on growing its sales pipeline and onboarding new customers.
• The company will continue to monitor and address the risk factors outlined in the document.

Key Dates

Keywords

Catheter Precision, LockeT, VIVO, reverse stock split, revenue, cardiac electrophysiology, medical device, sales, NYSE American, VTAK